Singapore-based Everstone buys controlling stake in Calibre for Rs 1,000 cr

Singapore-headquartered, India-focused PE firm Everstone Capital bought a controlling stake in Calibre, a specialty ingredients player focused on pharma, in a reported Rs 1,000-crore deal

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Representative photo of a pharma company
Press Trust of India Mumbai
2 min read Last Updated : Dec 06 2020 | 10:13 PM IST

Singapore-headquartered, India-focused private equity firm Everstone Capital has acquired a controlling stake in Calibre, a specialty ingredients player focused on pharma, nutrition and personal care segments, in a reported Rs 1,000-crore deal.

Mumbai-headquartered Calibre, founded in 1984 by Ranjit Bhavnani in Gujarat, is a leading specialty ingredients player in the iodine derivatives, persulfates and perchlorates segments.

Though the companies did not disclose the deal value, a market source told PTI that the transaction is valued at around Rs 1,000 crore.

Calibre boasts of a customer base across 75 countries including the US, and those in Europe, Asia and exports contribute around two-thirds of its revenue, Everstone said in a statement, adding it has modern state manufacturing facilities at Sarigam in Gujarat.

While JM Financial advised Calibre, Everstone was advised by Alantra.

Sameer Sain, co-founder and chief executive of the Everstone Group said Calibre is a high quality and globally established player with significant untapped potential and combining the founder's entrepreneurial skills Everstone's operational expertise can help Calibre excel, innovate and scale.

Ranjit Bhavnani, the founder-chairman of Calibre said this deal marks the transformation of Calibre from a family owned to a professional one where we will continue to participate actively.

Everstone is one of the largest India and Southeast Asia-focused investors and its portfolio of companies include one of the largest nutraceutical ingredients businesses OmniActive, generic and specialty pharma maker Slayback Pharma and domestic pharma distribution platform Ascent Health amongst others.

Last year, Everstone exited from Rubicon Research generating returns of 4.5 times its investment.

The Everstone Group has assets of over USD 5 billion across private equity, real estate, infrastructure, and venture capital and its resource base spans New York, India, Singapore, London, and Mauritius.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :EverstonePharma Companies

First Published: Dec 06 2020 | 6:35 PM IST

Next Story